Lataa...
Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
BACKGROUND: Despite an enormous research effort, patients diagnosed with advanced colorectal cancer (CRC) still have low prognosis after surgical resection and chemotherapy. The major obstacle for CRC treatment is chemoresistance to front line anti-cancer drugs, such as 5-fluorouracil (5-FU) and oxa...
Tallennettuna:
| Julkaisussa: | Cancer Cell Int |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7713438/ https://ncbi.nlm.nih.gov/pubmed/33292253 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-020-01668-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|